CurrentCardio
Get Weekly

Heart failure & cardiomyopathiesRandomised controlled trial

Effects of empagliflozin in patients at risk of heart failure: the empire prevent metabolic trial

Eur J Prev CardiolPublished

  • Randomised controlled trial
  • double-blind
  • placebo-controlled
Read the original article ↗

Authors' conclusion

In high-risk patients with overweight or obesity, treatment with empagliflozin resulted in a potentially favourable reduction in eECV compared to placebo. Meanwhile, the drug did not affect EAT mass.

Study context

Population
Non-diabetic patients with body mass index (BMI) >28kg/m² and risk of heart failure (HF)Epicardial adipose tissue (EAT) analysis 165
Participants
191 patients
Comparison
Empagliflozin vs placebo
  • Empagliflozinn = 94
  • Placebon = 97reference
Primary endpoint
Baseline-adjusted mean differences in change of estimated extracellular volume (eECV) and ventricular EAT mass
Follow-up
180 days

Primary result

As reported in the abstract

eECV and ventricular EAT mass

Empagliflozin

−0.154

mean change · SD 0.257 · L

Placebo

−0.029

mean change · SD 0.261 · L

Empagliflozin vs PlaceboEstimated treatment difference, L (97.5% CI)P value
eECV
−0.123(−0.211 to −0.035)
padj=0.004
Empagliflozin vs PlaceboEstimated treatment difference, g (97.5% CI)P value
EAT mass
1.5(−3.8 to 6.7)
padj=1.00

Original publication

Effects of empagliflozin in patients at risk of heart failure: the empire prevent metabolic trial. Eur J Prev Cardiol. Published 8 January 2026. doi:10.1093/eurjpc/zwag010
Read the original article ↗PubMedCite RIS · BibTeX

Summarised from the published abstract; every number is checked against it